Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00295854 · ClinicalTrials.gov registry record · Phase 2
Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis
A Phase 2 study, sponsored by MediciNova.
- Completed
- Registry status
- Phase 2
- Development phase
- 296
- Enrollment target
NCT00295854 is a Phase 2 study that has completed, run by MediciNova. The registered enrollment target is 296 participants.
The verdict
NCT00295854, a Phase 2 study, has completed, sponsored by MediciNova.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 296 participants
- Enrollment target
Study Summary
To evaluate the safety and efficacy of 8 weeks of treatment with MN-001 at 500 mg bid, 500 mg once daily vs. placebo in patients with Interstitial Cystitis.
Interventions
- DRUG Placebo
- DRUG MN-001
- DRUG MN-001 BID
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 296 participants |
| Start Date | 2005-05 |
| Est. Completion | 2006-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00295854
The ClinicalTrials.gov registry entry for NCT00295854 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 296 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MediciNova, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00295854 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00295854 about?
NCT00295854 is a clinical study titled "Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis". To evaluate the safety and efficacy of 8 weeks of treatment with MN-001 at 500 mg bid, 500 mg once daily vs. placebo in patients with Interstitial Cystitis.
What is the current status of trial NCT00295854?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 296 participants. The study started on 2005-05. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00295854?
The interventions under investigation include: Placebo (DRUG), MN-001 (DRUG), MN-001 BID (DRUG).
Who is sponsoring clinical trial NCT00295854?
This trial is sponsored by MediciNova, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.